Cooperative Investigations, Clinical Studies, Conference Calls, New Drug Applications, and Strategies- Research Report on Insys,

   Cooperative Investigations, Clinical Studies, Conference Calls, New Drug
       Applications, and Strategies- Research Report on Insys, Integra,
                     Bio-Reference, Raptor, and Ironwood

PR Newswire

NEW YORK, December 17, 2013

NEW YORK, December 17, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Insys
Therapeutics, Inc. (NASDAQ: INSY), Integra Lifesciences Holdings Corporation
(NASDAQ: IART), Bio-Reference Laboratories, Inc. (NASDAQ: BRLI), Raptor
Pharmaceutical Corp. (NASDAQ: RPTP), and Ironwood Pharmaceuticals, Inc.
(NASDAQ: IRWD). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Insys Therapeutics, Inc. Research Report

On December 12, 2013, Insys Therapeutics, Inc. (Insys) announced that the
Company has received a subpoena from the Office of Inspector General of the
Department of Health and Human Services (HHS)with regard to an investigation
of potential violations that involve HHS programs. According to the Company,
subpoena requests documents regarding its product Subsys®, including Insys'
sales and marketing practices relating to the product. Insys stated that it
plans to cooperate with the investigation. The Full Research Report on Insys
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/4c7f_INSY

Integra Lifesciences Holdings Corporation Research Report

On December 12, 2013, Integra Lifesciences Holdings Corporation (Integra)
announced that its clinical study, Collagen Conduit Versus Microsurgical
Neurorraphy: 2-Year Follow Up of a Prospective, Blinded Clinical and
Electrophysiological Multicenter Randomized, Controlled Trial, has been
published in the December issue of The Journal of Hand Surgery. Integra stated
that the study concluded that entubulation nerve repair using the NeuraGen
Nerve Guide is as effective a method of repairing mixed motor and sensory
nerves as direct microsurgical suture. Simon Archibald, Chief Scientific
Officer of Integra, commented, "Demonstrating the equivalent effectiveness of
clinical entubulation repair of the major nerves of the forearm compared to
the ''gold standard'’ of microsurgical repair is a significant milestone for
this technology. This is the first report in the literature of a prospective,
randomized, controlled study of functional recovery following the repair of
major mixed motor and sensory nerves, using an approved and commercially
available nerve conduit. We hope that this new information will aid the
expansion and further adoption of the technique." The Full Research Report on
Integra Lifesciences Holdings Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/c0a4_IART

Bio-Reference Laboratories, Inc. Research Report

On December 12, 2013, Bio-Reference Laboratories, Inc. (Bio-Reference)
announced that it intends to release its Q4 FY2013 and full-year FY2013
earnings results on December 19, 2013, before the open of market trading. The
Company stated that it will hold a conference call on the same day at 10:30
a.m. EST, which will be hosted by Marc D. Grodman M.D., President and CEO.
Bio-Reference added that the live webcast of the call will be available at the
Company's website, and will be archived for 30 days after the call.The Full
Research Report on Bio-Reference Laboratories, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/1f59_BRLI

Raptor Pharmaceutical Corp. Research Report

On December 10, 2013, Raptor Pharmaceutical Corp. (Raptor) announced that it
has submitted an investigational new drug application (IND) to the US Food and
Drug Administration (FDA) for the clinical development of RP103 as a potential
treatment for Leigh syndrome and other mitochondrial disorders. The Company
informed that the RP103-MITO-001 trial is designed to evaluate the safety,
tolerability and efficacy of RP103 in patients with genetically confirmed
Leigh syndrome and other mitochondrial disorders. Raptor stated that the
initiation of the clinical trial is planned for Q1 2014 and interim results
are expected by the end of 2014. Patrice Rioux, M.D., Ph.D., Chief Medical
Officer of Raptor, commented, "Our extensive understanding of the mechanisms
of action of RP103 coupled with its potential tolerability, pharmacokinetics
and pharmacodynamics is generating substantial rationale to conduct further
studies in other orphan diseases. In addition to mitochondrial disorders
including Leigh syndrome, we are already conducting clinical trials of RP103
in NAFLD and Huntington's disease, and we will consider additional indications
as the science emerges."The Full Research Report on Raptor Pharmaceutical
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/a001_RPTP

Ironwood Pharmaceuticals, Inc. Research Report

On December 12, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) reported that
it will detail its strategy for establishing a leading gastrointestinal (GI)
therapeutic companyduring its Investor Day in New York City. The Company
stated that this strategy will leverage its strong development and commercial
capabilities in addressing GI disorders and as its pharmacologic expertise in
guanylatecyclase (GC) pathways.Peter Hecht, CEO of Ironwood, commented,"At
Ironwood, we've had the privilege to successfully discover, develop and
commercialize LINZESS, a medicine that is already helping hundreds of
thousands of adult patients suffering from IBS-C or CIC. We will leverage our
development and commercial expertise in an effort to address patient needs
across the upper and lower gastrointestinal tract, and we will build on our
deep pharmacologic expertise as we work to unlock value from our GC research
platform, with a goal of advancing seven GI clinical development programs with
multiple opportunities to generate proof of concept data over the next 24
months."Ironwood added that to execute its strategy, it will: Maximize
LINZESS, Leverage strong commercial capabilities, Advance robust GI pipeline
and guanylatecyclase (GC) research, and Prioritize investments in key value
drivers. The Full Research Report on Ironwood Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented byNidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.